Drug Delivery Systems: Entering the Mainstream

By Theresa M. Allen, P. Cullis. Science, 2004

4,318 citations recorded by the source corpus.

Subfields: Biomaterials, Molecular Biology, Pharmaceutical Science

View Paper: https://www.semanticscholar.org/paper/ab59a0d447f5ca185a5d1d52cb0f4867606644e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Molecular Biology

In Pharmaceutical Science

Citations in the corpus

Liposomes: structure, composition, types, and clinical applications (2022, background): “DDSs involve delivering the potentially active drug to the site of action via a nano-vehicle to enhance the pharmacological properties of free drugs and cover their undesirable features through improving drug pharmacokinetics and biodistribution, as well as acting as drug reservoirs [2, 3].”
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. (2006, background): “Although the first generation of liposomes was limited by modest drug encapsulation efficiencies and rapid clearance by the reticuloendothelial system, progressive optimization has resulted in more stable and long-circulating liposomes with increased deposition in tumors (1, 2), which provide potent”
High drug-loading nanomedicines: progress, current status, and prospects (2017, positive): “4 billion.(8,9) The average cost and time required to develop a new nanomedicine (approximately $20–$50 million and 3–4 years) are significantly lower than for a new chemical drug (approximately $500 million and over 10 years).”
Biomedical applications of functionalised carbon nanotubes. (2005, background): “Among the currently available delivery systems, which include liposomes, emulsions, polymers and microparticles (Lavan et al., 2003; Martin and Kohli, 2003; Allen and Cullis, 2004), carbon nanotubes (CNTs) have recently gained popularity as potential drug carriers, therapeutic agents and diagnostic ”
Liposomal drug delivery systems: from concept to clinical applications. (2013, background): “stream as sustained release drug delivery systems [243] for the in vivo delivery of everything from small molecule therapeutics to nucleic acids.”
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA (2012, methodology): “The amount of PEG-lipid required to coat the external surface of an LNP of a given size in this limit size model is given by Equation (1).”
Designing dendrimers for biological applications (2005, methodology): “A variety of carriers, including small-molecule substrates for cellular receptors and transporters, proteins, soluble polymers, micro/nanoparticulate polymers and liposomes, have been used for this purpos”